PFIZER INC

Pfizer partners with China’s Innovent Biologics on 12 early‑stage oncology programs, combining Innovent’s ADC tech with Pfizer’s global reach to accelerate breakthrough cancer treatments.

Pfizer’s share rise reflects a robust pipeline—from breakthrough mRNA vaccines to CRISPR‑based rare‑disease therapy—showing early‑phase promise and market optimism.

Pfizer’s latest market analysis shows a stable dividend strategy amid competitive oncology dynamics, patent cliffs, and targeted M&A plans.

Pfizer’s entry into the health‑and‑wellness market uses clinical expertise, AI‑driven precision nutrition, and subscription models to drive double‑digit growth, high margins, and value‑based reimbursement, positioning it as a future‑proof leader in …

Pfizer files S‑8 to issue 320 M shares, boosting capital for oncology R&D and confirming a solid 2026 outlook, while its earnings reinforce growth and product pipeline confidence.

Pfizer’s next earnings report shows modest quarterly gains but a sharp FY uptick driven by new obesity and rare‑disease drugs, highlighting patent cliffs, market‑access tactics, and M&A opportunities.

Pfizer’s recent corporate moves—expiring ASX convertible options and FDA‑approved VEPPANU—boost its financial health and expand precision breast‑cancer treatment options.

Pfizer’s FDA approval of Veppanu expands its breast‑cancer portfolio, boosting oncology prospects and reinforcing its market position amid patent‑cliff pressures.

Pfizer’s interim MagnetisMM‑5 data show ELREXFIO improves progression‑free survival in RRMM, promising a premium price and strong market impact.

Pfizer’s Vyndamax patent settlement extends exclusivity to 2031, boosting revenue and positioning the drug amid rising competition and value‑based pricing shifts.